Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 65-75

  Wyler, Beat ^a   Shao, Ying ^a   Schneider, Erasmus ^b   Cianfriglia, Maurizio ^c   Scheper, Rik J ^d   Frey, Beat M ^a   Gieseler, Frank ^e   Schmid, Luzius ^f   Twentyman, Peter R ^g   Lehnert, Manfred ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f Institute for Clinical Chemistry and Haematology   (Switzerland)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

doxorubicin; multidrug resistance; myeloma

Indexed keywords

AMSACRINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL; VINCRISTINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 8244261274     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.52649.x     Document Type: Article

References (67)

1. Abbaszadegan, M.R., Futscher, B.W., Klimecki, W.T., List, A. & Dalton, W.S. (1994) Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Research, 54, 4676-4679.
2. Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484-489.
3. Baas, F., Jongsma, A.P.M., Broxterman, H.J., Arceci, R.J., Housman, D., Scheffer, G.L., Riethorst, A., van Groeningen, M., Nieuwint, A.W.M. & Joenje, H. (1990) Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human cancer cell line. Cancer Research, 50, 5392-5398.
4. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
5. Barrand, M.A., Rhodes, T., Center, M.S. & Twentyman, P.R. (1993) Chemosensitization and drug accumulation effects of cyclosporin A. PSC-833, and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. European Journal of Cancer, 29A, 408-415.
6. Beck, W.T., Danks, M.K., Wolverton, J.S., Chen, M., Granzen, B., Kim, R. & Suttle, D.P. (1994) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Advances in Pharmacology, 29B, 145-169.
7. Biedler, J.L. (1994) Drug resistance: genotype versus phenotype: thirty-second G. H. A. Clowes memorial award lecture. Cancer Research, 54, 666-678.
8. Breuninger, L.M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S.A. & Kruh, G.D. (1995) Expression of multidrug resistance-associated protein in NIH/3T 3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Research, 55, 5342-5347.
9. Brock, I., Hipfner, D.R., Nielsen, B.S., Jensen, P.B., Deeley, R.G., Cole, S.P.C. & Sehested, M. (1995) Sequential coexpression of the multidrug resistance gene MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Research, 55, 459-462.
10. Bugg, B.Y., Danks, M.K., Beck, W.T. & Suttle, D.P. (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proceedings of the National Academy of Sciences of the United States of America, 88, 7654-7658.
11. Burden, D.A., Goldsmith, L.J. & Sullivan, D.M. (1993) Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. Biochemical Journal, 293, 297-304.
12. Chan, Y.T.-W., Ng, S.W., Eder, J.P. & Schnipper, L.E. (1993) Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. Journal of Biological Chemistry, 268, 2160-2165.
13. Chaudhary, P.M. & Roninson, I.B. (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. Journal of the National Cancer Institute, 85, 632-639.
14. Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Gottesman, M.M. & Roninson, I.B. (1986) Internal duplication and homology with bacterial transport proteins in the MDR-1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-389.
15. Chen, T.R. (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Experimental Cell Research, 104, 255-262.
16. Chomczynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156-159.
17. Cianfriglia, M., Willingham, M.C., Tombesi, M., Scagliotti, G.V., Frasca, G. & Chersi, A. (1994) P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug resistant cells. International Journal of Cancer, 56, 153-160.
18. Cole, S.P.C., Bhardway, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M.V. & Deeley, R.G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 25, 1650-1654.
19. Cole, S.P.C., Downes, H.F. & Slovak, M.L. (1989) Effects of calcium antagonists on the chemosensitivity of, two multidrug resistant human tumour cell lines which do not overexpress P-glycoprotein. British Journal of Cancer, 59, 42-46.
20. Cole, S.P.C., Sparks, K.E., Fraser, K., Loe, D.W., Grant, C.E., Wilson, G.M. & Deeley, R.G. (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research, 54, 5902-5910.
21. Coley, H.M., Amos, W.B., Twentyman, P.R. & Workman, P. (1995) Examination by laser scanning confocal fluorescence imaging microscopy of subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. British Journal of Cancer, 67, 1316-1323.
22. Dalton, W.S., Durie, B.G.M., Alberts, D.S., Gerlach, J.J. & Cress, A.E. (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Research, 46, 5125-5130.
23. r 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Research, 53, 1373-1379.
24. De Jong, S., Zijlstra, J.G., de Vries, E.G.E. & Mulder, N.H. (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell lines. Cancer Research, 50, 304-309.
25. Flens, M.J., Izquierdo, M.A., Scheffer, G.L., Fritz, J.M., Meijer, C.J.L.M., Scheper, R.J. & Zaman, G.J.R. (1994) Immutiochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Research, 54, 4557-4563.
26. Gottesman, M.M. & Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry, 62, 385-427.
27. Grant, C.E., Valdimarsson, G., Hipfner, D.R., Almquist, K.C., Cole, S.P.C. & Deeley, R.G. (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research, 54, 357-361.
28. Grogan, T.M., Spier, C.M., Salmon, S.E., Matzner, M., Rybski, J., Weinstein, R.S., Scheper, R.J. & Dalton, W.S. (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81, 490-495.
29. Hasegawa, S., Abe, T., Naito, S., Kotoh, S., Kumazawa, J., Hipfner, D.R., Deeley, R.G., Cole, S.P.C. & Kuwano, M. (1995) Expression of multidrug resistance-associated protein (MRP), MDR1, and topoisomerase II in human multidrug-resistant bladder cancer cell lines. British Journal of Cancer, 71, 907-913.
30. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F.D. & Zwelling, L.A. (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine resistant form of topoisomerase II. Cancer Research, 51, 4729-4731.
31. Ishikawa, H., Kawano, M.M., Okada, K., Tanaka, H., Tanabe, O., Sakai, A., Asaoku, H., Iwato, K., Nobuyoshi, M. & Kuramoto, A. (1993) Expression of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. British Journal of Haematology, 83, 68-74.
32. Izquierdo, M.A., van der Zee, A.G.J., Vermorken, J.B., van der Valk, P., Belien, J.A.M., Giaccone, G., Scheffer, G.L., Flens, M.J., Pinedo, H.M., Kenemans, P., Meijer, C.J.L.M., de Vries, E.G.E. & Scheper, R.J. (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. Journal of the National Cancer Institute, 87, 1230-1237.
33. Izquierdo, M.A., Shoemaker, R.H., Flens, M.J., Scheffer, G.L., Wu, L., Prather, T.R. & Scheper, R.J. (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. International Journal of Cancer, 65, 1-8.
34. Jedlitschky, G., Leir, I., Buchholz, U., Center, M. & Keppler, D. (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Research, 54, 4833-4836.
35. Kawasaki, E.S. & Wang, A.M. (1989) Detection of gene expression. PCR Technology (ed. by H. A. Ehrlich), pp. 89-97, Stockton Press, New York.
36. Kimura, K., Saijo, M., Ui, M. & Enomoto, T. (1994) Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. Journal of Biological Chemistry, 269, 1173-1176.
37. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T7. Nature, 227, 680-685.
38. Lee, M.S., Wang, J.C. & Beran, M. (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170kDa form of human topoisomerase II. Journal of Molecular Biology 223, 837-843.
39. Lehnert, M., Dalton, W.S., Roe, D., Emerson, S. & Salmon, S.E. (1991) Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood, 77, 348-354.
40. Lincke, CR., van der Bliek, A.M., Schuurhuis, G.J., van der Velde-Koerts, T., Smith, J.J.M. & Borst, P. (1990) The multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human MDR-1 cDNA. Cancer Research, 50, 1779-1785.
41. Linsenmeyer, M.E., Jefferson, S., Wolf, M., Matthews, J.P., Board, P.G. & Woodcock, D.M. (1992) Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. British Journal of Cancer, 65, 471-475.
42. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J. & Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464-2469.
43. Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1996) Biology of the multidrug resistance-associated protein. MRP. European Journal of Cancer, 32A, 945-957, 1996.
44. Müller, M., Meijer, C., Zaman, G.J.R., Borst, P., Scheper, R.J., Mulder, N.H., de Vries, E.G.E. & Jansen, P.L.M. (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proceedings of the National Academy of Sciences of the United States of America, 91, 13033-13037.
45. Makajima-Ikjima, S., Hamada, H., Reddy, P. & Kakunaga, T. (1985) Molecular structure of the human cytoplasmic β-actin gene: interspedes homology of sequences in the introns. Proceedings of the National Academy of Sciences of the United States of America, 82, 6153-6137.
46. Nitiss, J.L & Beck, W.T. (1996) Antitopoisomerase drug action and resistance. European Journal of Cancer, 32A, 958-966.
47. Patel, S. & Fisher, L.M. (1993) Novel selection and genetic characterization of an etoposide-resistant human leukaemic CCRF-CEM cell line. British Journal of Cancer, 67, 456-465.
48. Sahai, B.M. & Kaplan, J.G. (1986) A quantitative decatenation assay for type II topoisomerases. Analytical Biochemistry, 156, 364-379.
49. Salmon, S.E., Dalton, W.S., Grogan, T.M., Plezia, P., Lehnert, M., Roe, D.J. & Miller, T.P. (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78, 44-50.
50. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research, 53, 1475-1479.
51. Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer, C.J.L.M., Clevers, H.C. & Scheper, R.J. (1995) The drug resistance-related protein LRP is the human major vault protein. Nature Medicine, 1, 578-582.
52. Schneider, E., Cowan, K.H., Bader, H., Toomey, S., Schwartz, G.N., Karp, J.E., Burke, P.J. & Kaufmann, S.H. (1995a) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85, 186-193.
53. Schneider, E., Horton, J.K., Yang, C-H., Nakagawa, M. & Cowan, K.H. (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Research, 54, 152-158.
54. Schneider, E., Yamazaki, H., Sinha, B.K. & Cowan, K.H. (1995b) Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistance-associated protein involves increased drug accumulation. British Journal of Cancer, 71, 738-743.
55. Shao, Y. de Giuli, R., Wyler, B. & Lehnert, M. (1995) Overexpression of MDR1/P-glycoprotetn and MRP but not LRP is mutually exclusive in multidrug resistant human myeloma cells selected with doxorubicin. (Abstract). Proceedings of the American Association for Cancer Research, 36, 2006.
56. Sonneveld, P., Durie, B.G.M., Lokhorst, H.M., Marie, J.-P., Solbu, G., Suciu, S., Zittoun, R., Löwenberg, B. & Nooter, K. (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet, 340, 255-259.
57. Sonneveld, P., Schoester, M. & de Leeuw, K. (1994) Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. Journal of Clinical Oncology, 12, 1584-1591.
58. Tew, K.D. (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Research, 54, 4313-4320.
59. Tsai-Pflugfelder, M., Liu, L.F., Liu, A., Tewey, K.M., Whang-Peng, J., Turid, K., Huebner, K., Croce, C.M. & Wang, J.C. (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proceedings of the National Academy of Sciences of the United States of America, 85, 7177-7181.
60. Van der Bliek, A.M., Kooiman, P.M., Schneider, C. & Borst, P. (1988) Sequence of mdr3 cDNA. encoding a human P-glycoprotein. Gene, 71, 401-411.
61. Versantvoort, C.H.M., Broxterman, H.J., Bagrij, T., Scheper, R.J. & Twentyman, P.R. (1995a) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. British Journal of Cancer, 72, 82-89.
62. 4 sub-lines with increasing adriamycin resistance. International Journal of Cancer, 61, 375-380.
63. Wells, N.J., Fry, A.M., Guano, F., Norbury, C. & Hickson, I.D. (1995) Cell cycle phase-specific phosphorylation of human topoisomerase IIa. Journal of Biological Chemistry, 270, 28357-28363.
64. Wossner, R.D., Mattern, M.R., Mirabelli, C.K., Johnson, R.K. & Drake, F.H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T 3 cells. Cell Growth and Differentiation, 2, 209-214.
65. Zaman, G.J.R., Flens, M.J., van Leusden, M.R., de Haas, M., Mülder, H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Broxterman, H.J. & Borst, P. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proceedings of the National Academy of Sciences of the United States of America, 91, 8822-8826.
66. Zaman, G.J.R., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elfering, R.P.J., Baas, F. & Borst, P. (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proceedings of the National Academy of Sciences of the United States of America, 92, 7690-7694.
67. Zaman, G.J.R., Versantvoort, C.H.M., Smit, J.J.M., Eijdems, E.W.H.M., de Haas, M., Smith, A.J., Broxterman, H.J., Mulder, N.H., de Vries, E.G.E., Baas, F. & Borst, P. (1993) Analysis of the expression of MRP. the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Research, 53, 1747-1750.